Dementia and Alzheimer Disease

Epilepsy

Headache and Migraine

Movement Disorders

Multiple Sclerosis

Neuromuscular

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

eNewsletter

Print Subscription

Articles

The committee all agreed that tofersen presents a favorable risk-benefit profile in this particularly challenging patient population. 

FDA AdComm on Tofersen Supports NfL as Surrogate End Point of Clinical Benefit, But Is It Enough for Approval?

After results indicated significant slowing of ALS disease progression, Coya noted it plans to file an IND with the FDA in the second half of 2023 for a potential clinical study thereafter.

Treg Suppressing Agent COYA 302 Shows Slowing of ALS Disease Progression

If approved, ABBV-951 will become the first subcutaneous delivery of carbidopa/levodopa, often considered the standard of care for symptom management for patients with Parkinson disease.

FDA Issues Complete Response Letter for AbbVie’s 24-Hour Continuous Carbidopa/Levodopa Pump

The professor of neurology and pediatrics at University of Rochester Medical Center shared her thoughts on the 2023 MDA Clinical and Scientific Conference, and the progress made in the treatment of neuromuscular disorders. 

NeuroVoices: Emma Ciafaloni, MD, on Mounting Progress in the Neuromuscular Field, Duchenne Muscular Dystrophy

The neurologist and migraine expert from NYU Langone Health.

Videos

The neurologist and migraine expert from NYU Langone Health shared her reactions to the recently approved zavegepant nasal spray (Zavzpret; Pfizer) for the treatment of migraine. [WATCH TIME: 5 minutes]  

Newly Approved Migraine Nasal Spray Offers Alternative Treatment to Injections, Oral Medications: Shae Datta, MD

Slideshows

Here's the latest multidisciplinary MS research published online first in the International Journal of MS Care.

IJMSC Online First: March 2023

Director, Comprehensive Epilepsy Center, NYU Langone Health

The director of the Comprehensive Epilepsy Center at NYU Langone discussed the importance of healthy eating habits and whether all individuals with epilepsy should consider dieting early in their life. [WATCH TIME: 4 minutes]

Importance of Establishing Healthy Eating Habits in Epilepsy: Orrin Devinsky, MD

The vascular neurologist at Cleveland Clinic provided an overview of a study that assessed the extent HbA1c impacts the relationship between mechanical thrombectomy and poor outcomes. [WATCH TIME: 3 minutes]

Effect of HbA1c Elevation, Glycemic Control Following Mechanical Thrombectomy: David Baker, DO

The multiple sclerosis condition center is a resource for clinical news on the diagnosis, treatment, and management of multiple sclerosis. | NeurologyLive.


Multiple Sclerosis | Clinical Neurology News | NeurologyLive

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

Spotlight

MDA 2023

NMOSD

Narcolepsy

Parkinson Disease

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1.125rem

Clinical

EMD-22-NRD0193 - /clinical/multiple-sclerosis

 multiple sclerosis (MS) clinical focus page offers information, podcasts, videos, and news about the latest study and clinical trial findings, FDA actions, clinical guideline updates, and expert interviews related to the care and management of patients with MS, including relapsing MS and progressive MS, as well as related disorders such as neuromyelitis optica spectrum disorder.

's featured content in the carousel below.

 to subscribe on your favorite streaming service.

 podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

Episode 83, "The ARISE Study and Using DMTs in RIS," features an exclusive interview with Darin Okuda, MD, FAAN, FANA, director of Neuroinnovation and Multiple Sclerosis & Neuroimmunology Imaging Program at UT Southwestern Medical Center. He spoke about the phase 2 ARISE study assessing dimethyl fumarate (Tecfidera; Biogen) in patients with radiologically isolated syndrome, the significance of the findings, next steps in validating this therapy, and more.

, a streaming channel from MJH Life Sciences

. Check out new content and shows every day, only at

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

CNM-Au8 Shows Positive Findings on MS-Related Biomarkers of Whole Brain, White Matter

Aducanumab’s Label Updated to Include Risks on Brain Bleeding

Primary Care Physicians Show Greater Confidence in Diagnosing Alzheimer Disease Through DISCERN Skin Test

FDA Approves Extended-Release Deutetrabenazine for Huntington Disease Chorea, Tardive Dyskinesia

 – Overview of ARISE and conduct of study

 – Potential subgroup responders to dimethyl fumarate

 – Efforts to improve the detection of radiologically isolated syndrome

 – Next steps of research following ARISE

 – Closing thoughts on significance of the study

 podcast. Be sure to leave a rating and review for the show. Thanks for listening!

Hoping to listen on your favorite podcast app? See below:

REFERENCE
Okuda DT, Kantarci O, Lebrun-Frenay C, et al. Dimethyl fumarate delays multiple sclerosis radiologically isolated syndrome. 

 2023;93(3):604-614. doi:10.1002/ana.26555

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Darin Okuda, MD. [LISTEN TIME: 21 minutes]

Episode 83: The ARISE Study and Using DMTs in RIS

Episode 76, "ECTRIMS 2022 and the Latest in MS Advances," features exclusive interviews with a number of experts in the clinical care of MS who were in attendance at the 2022 ECTRIMS Congress, including Darin T. Okuda, MD, FAAN, FANA, director of Neuroinnovation and Multiple Sclerosis & Neuroimmunology Imaging Program at UT Southwestern Medical Center; Federica Picariello, PhD, a health psychologist and postgraduate research associate at King's College London; Brenda Banwell, MD, chief of the Division of Neurology and codirector of the Neuroscience Center at the Children's Hospital of Philadelphia; Riley Bove, MD, associate professor of neurology, University of California, San Francisco; Tomas Kalincik, MD, PhD, Dame Kate Campbell Professorial Fellow, head of the Clinical Outcomes Research Unit at the University of Melbourne, and head of the MS Centre at the Royal Melbourne Hospital; and Marisa McGinley, DO, a neurologist at the Mellen Center for MS at Cleveland Clinic. 

They joined the show to recap their experience at the 2022 ECTRIMS Congress in Amsterdam, the Netherlands, and highlight some of the key topics of discussion and data presentations from the annual meeting.

Click here for more coverage of ECTRIMS 2022

. Check out new episodes of a variety of shows, airing every single day, only on

Episode Breakdown

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Darin Okuda, MD; Federica Picariello, PhD; Brenda Banwell, MD; Riley Bove, MD; Tomas Kalincik, MD, PhD; and Marisa McGinley, DO. [LISTEN TIME: 34 minutes]

Episode 76: ECTRIMS 2022 and the Latest in MS Advances

Episode 75, "Focusing on the Future of Neurology," features a trio of exclusive interviews with the chairs of the recently hosted International Congress on the Future of Neurology (IFN), including Stephen Krieger, MD, professor of neurology and neurologist at the Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai; Richard Isaacson, MD, director of the Center for Brain Health at the Florida Atlantic University Schmidt College of Medicine; and Jessica Ailani, MD, associate professor of neurology and director of the MedStar Georgetown Headache Center. They joined the show to recap their experience at the 2022 IFN meeting, discuss the value of cross-specialty interactions, share their perspective on the future of their fields, and more.

The 4th Annual International Congress on the Future of Neurology

 showcased the most recent advancements in neurologic disorders, featuring practice-changing discussions and presentations of strategies for incorporating new therapies into practice, as well as a comprehensive overview of pharmacological and nonpharmacological modalities.

Occurring over 2 days, the educational program delivered information through a mix of clinical data presentations, case-based discussions, and robust Q&A sessions. Each year, this symposium brings together world-renowned experts in their respective fields to discuss the impact of new evidence and novel agents in the treatment of neurologic disorders in a highly practical and engaging format.

To learn more about the IFN Congress and other Physician's Education Resource CME activities, visit

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Stephen Krieger, MD; Richard Isaacson, MD; and Jessica Ailani, MD. [LISTEN TIME: 24 minutes]

Episode 75: Focusing on the Future of Neurology

Episode 73, "Updates in Epilepsy Treatment," features an exclusive interview with Ambereen Mehta, MD, MPH, palliative care physician and assistant professor of medicine, Johns Hopkins Bayview Medical Center. She joined the show to discuss palliative care and its evolving role in the care paradigm for patients with chronic neurologic disease, as well as its history in the United States, how it differs from hospice care, and more.

To learn more about neuropalliative care, head to our 

International Neuropalliative Care Society (INPCS) partner page

FDA Accepts Application for Trofinetide in Rett Syndrome

LIFT-AD Study Amended to Assess Alzheimer Disease Agent Fosgonimeton as Monotherapy

Tolerizing MS Vaccine Displays Efficacy in Model of Relapsing-Remitting Multiple Sclerosis

REFERENCES
1. Shemme AJ, Phillips JN, Bloise R, Koehler TJ, Gorelick PB, Francis BA. The Impact of a Neurocritical Care and Neuropalliative Collaboration on Intensive Care Unit Outcomes. 

. 2022;39(6):687-694. doi:10.1177/10499091211060055
2. Mehta AK, Wright SM, Wu DS, Harris CM. Palliative Care Involvement in Patients Hospitalized in the United States with Aneurysmal Subarachnoid Hemorrhage. 

. 2021;24(10):1555-1560. doi:10.1089/jpm.2021.0116
3. Williamson TL, Adil SM, Shalita C, et al. Palliative Care Consultations in Patients with Severe Traumatic Brain Injury: Who Receives Palliative Care Consultations and What Does that Mean for Utilization? 

. 2022;36(3):781-790. doi:10.1007/s12028-021-01366-2
4. Bužgová R, Kozáková R, Bar M. The effect of neuropalliative care on quality of life and satisfaction with quality of care in patients with progressive neurological disease and their family caregivers: an interventional control study. 

. 2020;19(1):143. doi:10.1186/s12904-020-00651-9
5. Mehta AK, Jackson NJ, Wiedau-Pazos M. Palliative Care Consults in an Inpatient Setting for Patients With Amyotrophic Lateral Sclerosis. 

. 2021;38(9):1091-1098. doi:10.1177/1049909120969959
6. Lou W, Granstein JH, Wabl R, Singh A, Wahlster S, Creutzfeldt CJ. Taking a Chance to Recover: Families Look Back on the Decision to Pursue Tracheostomy After Severe Acute Brain Injury. 

. 2022;36(2):504-510. doi:10.1007/s12028-021-01335-9.
7. Miyasaki JM, Kluger BM (ed). 

. Neuropalliative Care - Part I. 2022;190:2-243
8. Lou W, Granstein JH, Wabl R, Singh A, Wahlster S, Creutzfeldt CJ. Taking a Chance to Recover: Families Look Back on the Decision to Pursue Tracheostomy After Severe Acute Brain Injury. 

. 2022;36(2):504-510. doi:10.1007/s12028-021-01335-9
9. Phillips JN, Besbris J, Foster LA, Kramer NM, Maiser S, Mehta AK. Models of outpatient neuropalliative care for patients with amyotrophic lateral sclerosis. 

. 2020;95(17):782-788. doi:10.1212/WNL.0000000000010831

International Neuropalliative Care Society (INPCS)

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Ambereen Mehta, MD, MPH. [LISTEN TIME: 40 minutes]

Episode 73: The Role of Palliative Care in Neurology

Episode 69, "The Widespread Effects of DMT Waste in Multiple Sclerosis," features an exclusive interview with Darin T. Okuda, MD, professor of neurology and director of Neuroinnovation and the Multiple Sclerosis & Neuroimmunology Imaging Program at The University of Texas Southwestern Medical Center at Dallas; and Karin Cook, senior vice president of medical strategy and clinical ethnographer, Heartbeat Medical Communications. The pair spoke about their research into the wasted costs associated with disease-modifying therapies (DMTs) for patients with multiple sclerosis,

 what they've observed at their center, the wide-reaching impact of this waste on the healthcare continuum, and the future solutions that are being worked on for this problem.

Click here for more coverage of this story: 

Multiple Sclerosis DMT Waste Is Staggering, New Study Shows

Zonisamide Oral Suspension FDA-Approved for Partial Seizures in Epilepsy

FT218 Receives Tentative Approval for EDS, Cataplexy in Adults With Narcolepsy

FDA Clears Rapid Hyperdensity Tool for Inclusion in RapidAI Platform for Neurovascular Conditions

ALS Therapy Tofersen Has NDA Accepted by FDA, Granted Priority Review

REFERENCE
1. Okuda DT, Burgess KW, Cook K, McCreary M, Winkler MD, Moog TM. Hiding in plain sight: the magnitude of unused disease-modifying therapies in multiple sclerosis and strategies for reducing the economic burden. 

 2022;63:103920. doi:10.1016/j.msard.2022.103920

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Darin T. Okuda, MD, and Karin Cook. [LISTEN TIME: 55 minutes]

Episode 69: The Widespread Effects of DMT Waste in Multiple Sclerosis

Episode 65, "2022 CMSC Annual Meeting Highlights," features interviews with a number of individuals who presented data and spoke at the Consortium of Multiple Sclerosis Centers Annual Meeting, on topics ranging from women with multiple sclerosis and the importance of measuring cognition in MS, to the characterization of relapse attacks in neuromyelitis optical spectrum disorder and the use of spinal cord atrophy as a biomarker of disease progression, to the potential to save time reviewing complex patient histories, and more.

. Check out new episodes every Tuesday and Thursday only on

Riley Bove, MD, associate professor of neurology at UCSF Weill Institute for Neurosciences

Blake E. Dewey, PhD, postdoctoral researcher at Johns Hopkins Multiple Sclerosis Center

Bruce Cree, MD, PhD, MAS, clinical research director of the UCSF Multiple Sclerosis Center

John DeLuca, PhD, senior vice president of research at the Kessler Foundation and professor at Rutgers University Medical School

Shuvro Roy, MD, clinical fellow at Johns Hopkins University

Tanuja Chitnis, MD, director of the pediatric multiple sclerosis center at Massachusetts General Hospital

Click here for more coverage of CMSC 2022.

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Riley Bove, MD; Blake E. Dewey, PhD; Bruce Cree, MD, PhD, MAS; John DeLuca, PhD; Shuvro Roy, MD; and Tanuja Chitnis, MD. [LISTEN TIME: 26 minutes]

Episode 65: 2022 CMSC Annual Meeting Highlights

Episode 61, "2022 AAN Annual Meeting Highlights," features interviews with a number of individuals who presented data and spoke at the American Academy of Neurology Annual Meeting, on topics ranging from COVID-19's clinical presentation, overall trends in the care of patients with multiple sclerosis, the potential of regenerative medicine in traumatic brain injury, the real-world and long-term use of new therapy for Lennox-Gastaut syndrome, the optimal timing for the newest therapy in neuromyelitis optica spectrum disorder, the Axon Registry and incorporating EHR information into its data collection, and the impact of the pandemic on clinician burnout and mental health. Those featured include Jennifer Frontera, MD; Stephen Krieger, MD; Peter McAllister, MD; Kelly Knupp, MD, MSCS; Bruce Cree, MD, PhD, MAS; Shrujal Baxi, MD, MPH; and Indu Subramanian, MD.

Note: As part of AAN policy for the Annual Meeting, all individuals were asked to remain masked throughout the week, so there may be some moments of muffled noises as participants adjust or shift their masks.

Click here for more coverage of AAN 2022.

American Academy of Neurology Annual Meeting

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Jennifer Frontera, MD; Stephen Krieger, MD; Peter McAllister, MD; Kelly Knupp, MD, MSCS; Bruce Cree, MD, PhD, MAS; Shrujal Baxi, MD, MPH; and Indu Subramanian, MD. [LISTEN TIME: 32 minutes]

Episode 61: 2022 AAN Annual Meeting Highlights

 podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis (MS), Parkinson disease, dementia, sleep disorders, and more.

Episode 60, "Improving Care and Raising Awareness for NMOSD," features an exclusive interview with Friedmann Paul, MD, head, Clinical Neuroimmunology Research Group, NeuroCure Clinical Research Center, and head, Clinical and Experimental Neuroimmunology, Experimental and Clinical Research Center, Charité–Universitätsmedizin Berlin. He shared his perspective on the state of care in neuromyelitis optica spectrum disorder (NMOSD), the need to raise awareness for symptomatic care and patient challenges, and the potential of novel therapeutic approaches to improve care and possibly cure the disorder.

The stories highlighted in this episode's Neurology News Minute can be found here:

Donepezil Transdermal System Wins FDA Approval to Treat Alzheimer Disease Dementia

Sarepta Details Phase 3 EMBARK Study in DMD

Ganaxolone Wins Landmark Approval for CDKL5 Deficiency Disorder

Mind Moments™, a podcast from NeurologyLive®, brings you an exclusive interview with Friedmann Paul, MD. [LISTEN TIME: 27 minutes]

Episode 60: Improving Care and Raising Awareness for NMOSD

Episode 57, "Invisible Symptoms: Cognition and MS," features an exclusive interview with Dhanashri P. Miskin, MD, clinical assistant professor of neurology, 

. She offered her insight into the role that cognitive impairment plays as a symptom of multiple sclerosis (MS), the current approach to treatment and management for patients, and what challenges remain for the field to address.

1-Week Epworth Sleepiness Scale for Children and Adolescents Validated for Pediatric Narcolepsy

Baclofen Oral Suspension Approved for Treatment of Spasticity in Multiple Sclerosis

Phase 2 Study of CY6463 in Alzheimer Disease With Vascular Pathology Initiated

Vickie and Jack Farber Institute for Neuroscience

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Dhanashri P. Miskin, MD. [LISTEN TIME: 39 minutes]

Episode 57: Invisible Symptoms: Cognition and MS

Episode 56, "Epstein-Barr Virus's Relationship With Multiple Sclerosis," features an exclusive interview with 

, director, Ochsner Multiple Sclerosis Center, and an investigator in the clinical study of the Epstein-Barr virus (EBV)-targeted agent, ATA188 (Atara Biotherapeutics).

 She offered her perspective on the recent data from Ascherio et al on the relationship between EBV and multiple sclerosis (MS) that suggest it may be a root cause of the disease,

 as well as background on the decades of research that have led to this point and the potential of therapies that target EBV and the B cells it infects for patients with MS.

Roche Designing New Phase 2 Trial of Tominersen in Huntington Disease

Risdiplam Gets Priority Review for Presymptomatic SMA in Babies Under 2 Months

Diverse Enrollment, Primary End Point Announced for Phase 4 ENVISION Study of Aducanumab

Have you nominated your Giant of Multiple Sclerosis? Help us recognize and celebrate pioneers, innovators, and leaders in MS. 

REFERENCES
1. Bar-Or A, Pender MP, Hodgkinson SJ, et al. Updated open-label extension clinical data and new magnetization transfer ratio imaging data from a Phase I study of ATA188, an off-the-shelf, allogeneic Epstein-Barr virus-targeted T-cell immunotherapy for progressive multiple sclerosis. Presented at ECTRIMS Congress; October 13-15, 2021; Poster P638.
2. Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. 

Published online January 13, 2022. doi:10.1126/science.abj8222

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Bridget A. Bagert, MD, MPH. [LISTEN TIME: 32 minutes]